Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

NCT03349203 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

EGF-R Positive Non-Small Cell Lung Cancer

Interventions

DRUG: Icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.